varicella zoster immune globulin (human)
Trade name: varizig
BiologicalapprovedOrphan Drug FDA
Approved
Dec 20, 2012
Clinical trial activity
2 trials · 4 clinical orgs · 2 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2006 (NCT00338442)
Timeline
2000s
- Nov 7, 2006
Orphan Drug Designation
2010s
- Mar 30, 2012
Cangene — First NDA Organization
- Mar 30, 2012
Cangene — NDA Organization
- Dec 20, 2012
Earliest FDA Approval
- Dec 20, 2012
Kamada, Ltd. — NDA Secondary Org
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Studied for
Mechanism of action
- Human herpesvirus 3Immunity, passive
Human herpesvirus 3 immunity, passive
Approval history
- approvedDec 20, 2012
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS33T61IWL27 ↗
Also known as
- human herpesvirus 3 immune globulin
- human varicella-zoster immune globulin
- varicella zoster immune globulin
- varicella-zoster immune globulin
- varicella-zoster immune globulin
- varicella zoster immune globulin human
- varicella zoster immune globulin (human)
- varicella zoster immune globulin (human)
- varicella-zoster immune globulin human
- varicellon
- varizig
- varizig
- varizig
- vzig
- vzv immune globulin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06068608 | Phase 1 | Oct 5, 2023 | Guangzhou Trinomab Biotech Co., Ltd., ICON |
| NCT00338442 | N/A | Feb 1, 2006 | Cangene, FFF Enterprises |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cangene | For profit | 1 | 1 | 1 | 2006 |
| FFF Enterprises | For profit | 1 | 0 | 1 | 2006 |
| Guangzhou Trinomab Biotech Co., Ltd. | Government | 1 | 1 | 1 | 2023 |
| ICON | For profit | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Cangene | For profit | NDA | Mar 30, 2012 |
| Kamada, Ltd. | For profit | NDA2 | Dec 20, 2012 |